Press release
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Severe Asthma Treatment Landscape. Click here to read more @ Severe Asthma Pipeline Outlook [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Severe Asthma Pipeline Report
* In January 2025:- AstraZeneca:- This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.
* In January 2025: Upstream Bio Inc.:- The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
* In January 2025:- Incyte Corporation:- A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
* DelveInsight's Severe Asthma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
* The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Promising Severe Asthma Therapies such as Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326 , and others.
Stay informed about the cutting-edge advancements in Severe Asthma treatments. Download for updates and be a part of the revolution in Respiratory Diseases care @ Severe Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Severe Asthma Emerging Drugs
* GSK3511294: GlaxoSmithKline
GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline, for the treatment of asthma. GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of severe asthma.
* BSI-045B: Biosion
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion's collaboration partner - CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.
* Mepolizumab: Bio-Thera Solutions
Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months' duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.
Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight's detailed report now! @ Severe Asthma Treatment Drugs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Severe Asthma Companies
Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Severe Asthma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Asthma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Severe Asthma Pipeline Report
* Coverage- Global
* Severe Asthma Companies- Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
* Severe Asthma Therapies- Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
* Severe Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Severe Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Severe Asthma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Severe Asthma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK3511294: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BSI-045B: Biosion
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Mepolizumab: Bio-Thera Solutions
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Severe Asthma Key Companies
* Severe Asthma Key Products
* Severe Asthma- Unmet Needs
* Severe Asthma- Market Drivers and Barriers
* Severe Asthma- Future Perspectives and Conclusion
* Severe Asthma Analyst Views
* Severe Asthma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-asthma-fda-approvals-clinical-trials-emerging-drugs-pipeline-insights-and-companies-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dyspepsia-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight here
News-ID: 3849958 • Views: …
More Releases from ABNewswire
Global Postbiotics Market Set to Reach USD 224.8 Million by 2030, Growing at 8.9 …
Postbiotics Market by Source (Bacteria, Yeast), Application (Functional Food & Beverages, Dietary Supplements, Animal Feed, Cosmetics & Personal Care, and Pharmaceuticals), Form, Function, Manufacturing Technology, and Region - Global Forecast to 2030
The postbiotics market [https://www.marketsandmarkets.com/Market-Reports/postbiotics-market-237110254.html] is valued at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, growing at a CAGR of 8.9%. Growth is being fueled by rising consumer awareness of the link…
Acrylic Resins Market Size, Competitor Ranking Analysis, Market Trend Forecast R …
The Acrylic Resins Market is growing steadily, driven by demand in coatings, construction, automotive, and electronics. Key players like BASF, Dow, Mitsubishi Chemical Group, Sumitomo Chemical, and Arkema are leading with innovative, durable, and eco-friendly resin solutions. Their global reach and strong R&D capabilities ensure sustainable advancements, meeting evolving industry needs across diverse end-use applications.
The acrylic resins market is projected to reach USD 28.55 billion by 2030 from USD 21.89…
Decorative Foils Market: Sales Volume, Size, Share, Price Development Trend Fore …
The Decorative Foils Market is witnessing steady growth, driven by rising demand in furniture, flooring, and interior design. Key players such as TOPPAN Holdings, Schattdecor, and SURTECO are leading innovation with advanced printing, embossing, and eco-friendly solutions. Their global presence and diverse product portfolios ensure sustainable, high-quality surfaces that meet evolving consumer and industrial design trends worldwide.
The Decorative Foils Market is projected to grow at a CAGR of 4.8%, reaching…
Battery Materials Market Size, Trends, Growth: Global Forecast 2025-2030 | Top K …
The Battery Materials Market is expanding rapidly, driven by the surging demand for electric vehicles, energy storage, and consumer electronics. Key players such as BASF, POSCO Future M, Asahi Kasei, Umicore, and Sumitomo Metal Mining are leading innovation with advanced cathode, anode, and separator materials, ensuring sustainable supply chains and supporting the global shift toward clean energy solutions.
The Global Battery Materials Market is projected to grow from USD 83.95 billion…
More Releases for Severe
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763
This latest report researches the industry structure, sales, revenue,…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
